文献速递免疫规划传染病防控与疫情报告

VSV载体共表达RSV F与G蛋白在棉鼠模型中产生协同保护作用

Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.
PubMed 文献 · Vaccine · 2021-10-23

本研究将RSV融合蛋白(F)、不同构象的稳定化F蛋白、附着糖蛋白(G)或G与F组合分别表达于水疱性口炎病毒(VSV)载体,经鼻内或皮下免疫棉鼠。结果显示,稳定化F蛋白免疫原性与保护性较差;G蛋白经鼻内接种可提供部分保护并诱导中等水平中和抗体;共表达G与F的VSV载体经鼻内接种最为成功,可诱导中和抗体并在上、下呼吸道抵御RSV攻击至少80天。

要点

  • VSV载体共表达RSV G与F蛋白经鼻内接种可协同诱导中和抗体并增强保护。
  • 稳定化F蛋白(pre-fusion或post-fusion)免疫原性与保护性低于未修饰F蛋白。
  • RSV G蛋白经鼻内接种较皮下接种可提高中和抗体水平与部分保护效果。

核心结论

  • VSV载体共表达RSV F与G蛋白可协同诱导RSV特异性中和抗体并提供抗感染保护。

研究设计与样本

  • 研究在VSV载体中分别表达RSV F、稳定化F(pre-fusion或post-fusion)、G或G与F组合,并以棉鼠为模型经鼻内或皮下免疫评价免疫原性。

主要发现

  • 稳定化F(pre-fusion或post-fusion)与未修饰F相比免疫原性弱且保护性差。
  • RSV G提供部分保护及中等水平中和抗体,鼻内接种较皮下接种改善。
  • 共表达G与F的VSV载体经鼻内接种诱导中和抗体,并对上、下呼吸道RSV攻击提供至少80天保护。

临床怎么用

  • 提示鼻内接种共表达G与F的VSV载体可作为RSV疫苗候选策略,但尚需进一步临床前与临床验证。

局限性

  • 研究仅基于棉鼠模型,尚未在人体中验证免疫原性与保护效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory syncytial virus (RSV) is one of the most important causes of respiratory disease in infants, immunocompromised individuals, and the elderly. Natural infection does not result in long-term immunity, and there is no licensed vaccine. Vesicular stomatitis virus (VSV) is a commonly used vaccine vector platform against infectious diseases, and has been used as a vector for a licensed Ebola vaccine. In this study, we expressed the RSV fusion (F) protein, the RSV F protein stabilized in either a pre-fusion or a post-fusion configuration, the attachment glycoprotein (G), or the G and F proteins of RSV in combination in a VSV vector. Cotton rats were immunized with these recombinants intranasally or subcutaneously to test immunogenicity. RSV F stabilized in either a pre-fusion or a post-fusion configuration proved to be poorly immunogenic and protective when compared to unmodified F. RSV G provided partial protection and moderate levels of neutralizing antibody production, both of which improved with intranasal administration compared to subcutaneous inoculation. The most successful vaccine vector was VSV expressing both the G and F proteins after intranasal inoculation. Immunization with this recombinant induced neutralizing antibodies and provided protection from RSV challenge in the upper and lower respiratory tract for at least 80 days. Our results demonstrate that co-expression of F and G proteins in a VSV vector provides synergistic effects in inducing RSV-specific neutralizing antibodies and protection against RSV infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Brakel KA, Binjawadagi B, French-Kim K, et al. Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model. Vaccine. 2021. PMID: 34702618. doi:10.1016/j.vaccine.2021.10.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。